Charles River Laboratories International Competitors

Thermo Fisher Scientific (NYSE:TMO) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Volatility & Risk

Thermo Fisher Scientific has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Insider & Institutional Ownership

87.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 92.3% of Charles River Laboratories International shares are held by institutional investors. 0.4% of Thermo Fisher Scientific shares are held by insiders. Comparatively, 1.9% of Charles River Laboratories International shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Thermo Fisher Scientific and Charles River Laboratories International's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Thermo Fisher Scientific and Charles River Laboratories International's gross revenue, earnings per share (EPS) and valuation.

Thermo Fisher Scientific has higher revenue and earnings than Charles River Laboratories International. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Thermo Fisher Scientific and Charles River Laboratories International, as reported by MarketBeat.

Thermo Fisher Scientific presently has a consensus target price of $536.8947, suggesting a potential upside of 18.06%. Charles River Laboratories International has a consensus target price of $286.4167, suggesting a potential downside of 9.58%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, research analysts clearly believe Thermo Fisher Scientific is more favorable than Charles River Laboratories International.

Summary

Thermo Fisher Scientific beats Charles River Laboratories International on 9 of the 14 factors compared between the two stocks.

Illumina (NASDAQ:ILMN) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Volatility & Risk

Illumina has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Illumina and Charles River Laboratories International, as reported by MarketBeat.

Illumina presently has a consensus target price of $374.50, suggesting a potential upside of 0.45%. Charles River Laboratories International has a consensus target price of $286.4167, suggesting a potential downside of 9.58%. Given Illumina's higher probable upside, research analysts clearly believe Illumina is more favorable than Charles River Laboratories International.

Profitability

This table compares Illumina and Charles River Laboratories International's net margins, return on equity and return on assets.

Insider & Institutional Ownership

90.0% of Illumina shares are held by institutional investors. Comparatively, 92.3% of Charles River Laboratories International shares are held by institutional investors. 0.4% of Illumina shares are held by insiders. Comparatively, 1.9% of Charles River Laboratories International shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Illumina and Charles River Laboratories International's gross revenue, earnings per share (EPS) and valuation.

Illumina has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Summary

Illumina beats Charles River Laboratories International on 8 of the 14 factors compared between the two stocks.

Charles River Laboratories International (NYSE:CRL) and Agilent Technologies (NYSE:A) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Volatility & Risk

Charles River Laboratories International has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Charles River Laboratories International and Agilent Technologies, as reported by MarketBeat.com.

Charles River Laboratories International presently has a consensus price target of $286.4167, indicating a potential downside of 9.58%. Agilent Technologies has a consensus price target of $107.4350, indicating a potential downside of 16.48%. Given Charles River Laboratories International's higher probable upside, equities analysts plainly believe Charles River Laboratories International is more favorable than Agilent Technologies.

Profitability

This table compares Charles River Laboratories International and Agilent Technologies' net margins, return on equity and return on assets.

Insider and Institutional Ownership

92.3% of Charles River Laboratories International shares are owned by institutional investors. 1.9% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Charles River Laboratories International and Agilent Technologies' gross revenue, earnings per share (EPS) and valuation.

Agilent Technologies has higher revenue and earnings than Charles River Laboratories International. Agilent Technologies is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Summary

Agilent Technologies beats Charles River Laboratories International on 8 of the 14 factors compared between the two stocks.

Charles River Laboratories International (NYSE:CRL) and Mettler-Toledo International (NYSE:MTD) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Volatility & Risk

Charles River Laboratories International has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Mettler-Toledo International has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Charles River Laboratories International and Mettler-Toledo International, as reported by MarketBeat.com.

Charles River Laboratories International presently has a consensus price target of $286.4167, indicating a potential downside of 9.58%. Mettler-Toledo International has a consensus price target of $1,048.3333, indicating a potential downside of 15.56%. Given Charles River Laboratories International's stronger consensus rating and higher probable upside, equities analysts plainly believe Charles River Laboratories International is more favorable than Mettler-Toledo International.

Profitability

This table compares Charles River Laboratories International and Mettler-Toledo International's net margins, return on equity and return on assets.

Insider and Institutional Ownership

92.3% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 93.2% of Mettler-Toledo International shares are owned by institutional investors. 1.9% of Charles River Laboratories International shares are owned by insiders. Comparatively, 3.2% of Mettler-Toledo International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Charles River Laboratories International and Mettler-Toledo International's gross revenue, earnings per share (EPS) and valuation.

Mettler-Toledo International has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Summary

Mettler-Toledo International beats Charles River Laboratories International on 9 of the 14 factors compared between the two stocks.

Charles River Laboratories International (NYSE:CRL) and Waters (NYSE:WAT) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Volatility & Risk

Charles River Laboratories International has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Charles River Laboratories International and Waters, as reported by MarketBeat.com.

Charles River Laboratories International presently has a consensus price target of $286.4167, indicating a potential downside of 9.58%. Waters has a consensus price target of $251.25, indicating a potential downside of 17.25%. Given Charles River Laboratories International's stronger consensus rating and higher probable upside, equities analysts plainly believe Charles River Laboratories International is more favorable than Waters.

Profitability

This table compares Charles River Laboratories International and Waters' net margins, return on equity and return on assets.

Insider and Institutional Ownership

92.3% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 91.8% of Waters shares are owned by institutional investors. 1.9% of Charles River Laboratories International shares are owned by insiders. Comparatively, 1.5% of Waters shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Charles River Laboratories International and Waters' gross revenue, earnings per share (EPS) and valuation.

Waters has lower revenue, but higher earnings than Charles River Laboratories International. Waters is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Summary

Charles River Laboratories International beats Waters on 9 of the 14 factors compared between the two stocks.

Charles River Laboratories International (NYSE:CRL) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Volatility & Risk

Charles River Laboratories International has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Charles River Laboratories International and Bio-Rad Laboratories, as reported by MarketBeat.com.

Charles River Laboratories International presently has a consensus price target of $286.4167, indicating a potential downside of 9.58%. Bio-Rad Laboratories has a consensus price target of $700.00, indicating a potential upside of 19.89%. Given Bio-Rad Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Charles River Laboratories International.

Profitability

This table compares Charles River Laboratories International and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Insider and Institutional Ownership

92.3% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 63.0% of Bio-Rad Laboratories shares are owned by institutional investors. 1.9% of Charles River Laboratories International shares are owned by insiders. Comparatively, 27.5% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Charles River Laboratories International and Bio-Rad Laboratories' gross revenue, earnings per share (EPS) and valuation.

Bio-Rad Laboratories has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.